IL6 and COVID-19: As in Case 5, in which the use of an anti-IL-6 agent was indicated, immunomodulation with biological agents has been used and seems to play an important role in adult patients with severe COVID-19, to whom the use of Tocilizumab was described for pharmacological inhibition of this interleukin.8,11